IMPROVING Patient care through technology
Point of Care System for Blood Coagulation Monitoring
Viscoelastic coagulation monitor - VCM™
Rapid Hemostasis Assessment
Viscoelastic coagulation testing is increasingly used to monitor real-time hemostasis with patients in trauma, surgery, obstetrics, major disease, and other settings, providing critical information not available from the most commonly used coagulation tests.
True Point of Care Solution
Entegrion’s viscoelastic coagulation monitor, VCM, is a next generation viscoelastic testing instrument that provides rapid, real-time hemostasis assessment. Designed as a true point of care solution, the VCM offers important advancements in an accessible, easy to use, and highly portable instrument.
Full Automation
The VCM system uses a small amount of fresh, whole blood, introduced into the instrument at the bedside with no chemical modifications. The fully automated test is free of chemical accelerants and the need to manipulate samples, saving valuable time and avoiding modifications to the native properties of the patient sample.
Portable Precision
VCM’s small footprint provides significant potential for applications in numerous clinical settings, including pre-hospital emergency medicine.
Future Outlooks
The VCM system has achieved regulatory clearance in Europe, and will be available in Europe and other regions that accept CE Marked products. The system has not been cleared for human clinical use in the United States.
For Veterinary Use:
For Human Use:
MEET OUR TEAM
Bert Valada
President and CEO
Bert Valada brings more than 30 years of experience in building and leading domestic and international world class healthcare organizations. After leaving multinational organizations, he has focused on the business development and transitioning of innovative healthcare companies in bringing new technologies and solutions to improve patient outcomes to market. Mr. Valada has supported the development and rollout of the VCM product line over the last seven years, taking a once highly complex and extremely valuable laboratory test and making it available at point of care worldwide.
Christopher Rumana, M.D.
Chairman of the Board
Dr. Rumana received his undergraduate and medical degrees from Northwestern University. He received his training in neurological surgery at Baylor College of Medicine, in Houston, Texas. In 1998 he completed his residency in neurological surgery and began his medical practice in Tallahassee, FL. He ultimately served for many years as President of Tallahassee Neurological Clinic, Chairman of the Division of Neurological Surgery at Tallahassee Memorial Hospital, and President and Chairman of Caduceus LLC. Additionally, he served as the Chief of the Medical Staff for Tallahassee Memorial Hospital and for many years served as a member of the Board of Directors in Tallahassee Memorial Hospital, ultimately culminating as Chairman of the Board. In 2018 he stopped his active medical practice and moved into a business advisory role, currently he serves as Chairman of the Board of Directors of two international medical companies and is either a fiduciary or advisory board member of several additional healthcare companies.
W. Brian Gibler, MD
Board Member
Dr. Gibler has over 30 years of professional healthcare experience in research, administration and clinical practice. Previously he was the President and CEO of University of Cincinnati Medical Center and prior to that he was the Chair of the Department of Emergency Medicine. His is currently Professor of Emergency Medicine at the University of Cincinnati College of Medicine and a Fellow both in the American College of Emergency Physicians and the American College of Cardiology. He earned his undergraduate degree from Brown and graduated from Vanderbilt University Medical School.
James True Martin, MD, CIME, FAADEP
Board Member
Dr. Martin is a neurologist in private practice at the Tallahassee Neurology Clinic, in Tallahassee, Florida. He has held a faculty appointment as clinical associate professor at Florida State University since 1983 and serves as an advisor for the Florida bar. He has eight years of research training and was the first student from Florida State University to be accepted to Vanderbilt Medical School based on academic achievements while waiving requirements for undergraduate graduation, and the university established a prestigious annual student award in his name. In addition to his numerous publications, he serves on several editorial advisory boards, is active in many professional organizations and retains several hospital affiliations in the Tallahassee area.
Pierre Noel, MD
Board Member
Dr. Noel is a Professor of Medicine at the Mayo Clinic College of Medicine and serves as the Director of Mayo Clinic Military Medicine and as a consultant in the Division of Hematology Oncology at Mayo Clinic Arizona. He joined Mayo in 1988 and left in 2000 to serve as the Chief of Hematology and a Senior Clinician for the National Institute of Health Clinical Center in Bethesda. In 2009 Dr. Noel served as a consultant for the White House Homeland and National Security Council in Washington, DC. Pierre served in the military from 1997 through 2010, and rejoined Mayo in 2010.
Ron Sacher, M.D.
Board Member
Dr. Sacher is the Director Emeritus of Hoxworth Blood Center and Emeritus Professor of Internal Medicine with the University of Cincinnati Academic Health Center. He also served as the Christian R. Holmes Professor and Interim Dean of the College of Medicine. Dr. Sacher previously served as Chairman of the Department of Laboratory Medicine and Director of Transfusion Medicine at Georgetown University Hospital and Professor of Medicine, Oncology and Pathology in the Hematology/Oncology division of the Department of Medicine. Dr. Sacher received his undergraduate and medical degrees from Witwatersrand University in Johannesburg, South Africa and completed his residency in Canada and a Fellowship in Hematology at Georgetown University Medical Center.
Kenneth Emancipator, M.D., D.A.B.P.
Board Member
Dr. Kenneth Emancipator is a board-certified pathologist who currently serves as Executive Director, Precision Medicine Companion Diagnostics at AbbVie. Previously, he was Executive Medical Director at Merck, where he defined the PD-L1 “TPS 50%” subgroup of non-small cell lung cancer, which led to the landmark approval of single agent Keytruda as a first line treatment for lung cancer. He also developed the “CPS” method for PD-L1 scoring, enabling first line approvals for Keytruda in head and neck squamous carcinoma, triple negative breast cancer, cervical cancer, and HER2-positive gastric cancer. He also played a major role in the landmark “tumor-agnostic” approval for Keytruda in “MSI-high” solid tumors. His 40-year career spans academia, the in vitro diagnostics industry, and pharma. He has held appointments at US National Institutes of Health, US Food and Drug Administration, Cornell University Medical College, Beth Israel Medical Center of New York, Siemens Diagnostics, and Abbott Laboratories.